Evidence map›Paper›PMID 20206893›Full record

ArticleJournal of cardiac failure2010

Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes.

Digish D Shah, Gregg C Fonarow, Tamara B Horwich

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiac failure, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 8 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 8 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Influence of Metformin Discontinuation on Readmission Rate in Patients With Acute Heart Failure.Journal of community hospital internal medicine perspectives · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Physiological monitoring of the complex multimorbid heart failure patient - diabetes and monitoring glucose control.European heart journal supplements : journal of the European Society of Cardiology · 2019
    Article
  18. Review
  19. Article
  20. Metabolic Effects of Metformin in the Failing Heart.International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Digish D ShahCedars Sinai Medical Center, Los Angeles, CA, USA.
Gregg C Fonarow
Tamara B Horwich
University of California, Los Angeles · USCedars-Sinai Medical Center · US

Funding

NHLBI NIH HHS 1K23 HL 085097NHLBI NIH HHS K23 HL085097
6 · The paper itself

Abstract

backgroundAlthough 25% to 44% of patients with heart failure (HF) have diabetes mellitus (DM), the optimal treatment regimen for HF patients with DM is uncertain. We investigated the association between metformin therapy and outcomes in a cohort of advanced, systolic HF patients with DM. METHODS AND

resultsPatients with DM and advanced, systolic HF (n = 401) were followed at a single university HF center between 1994 and 2008. The cohort was divided into 2 groups based on the presence or absence of metformin therapy. The cohort had a mean age of 56 +/- 11 years, left ventricular ejection fraction (LVEF) of 24 +/- 7%, with 42% being New York Heart Association (NYHA) III and 45% NYHA IV. Twenty-five percent (n = 99) were treated with metformin therapy. The groups treated and not treated with metformin were similar in terms of age, sex, baseline LVEF, medical history, and baseline glycosylated hemoglobin. Metformin-treated patients had a higher body mass index, lower creatinine, and were less often on insulin. One-year survival in metformin-treated and non-metformin-treated patients was 91% and 76%, respectively (RR = 0.37, CI 0.18-0.76, P = .007). After multivariate adjustment for demographics, cardiac function, renal function, and HF medications, metformin therapy was associated with a nonsignificant trend for improved survival.

conclusionIn patients with DM and advanced, systolic HF who are closely monitored, metformin therapy appears to be safe. Prospective studies are needed to determine whether metformin can improve HF outcome.

Indexed as

AgedCohort StudiesConfidence IntervalsDiabetes Mellitus, Type 2FemaleHeart Failure, SystolicHeart Function TestsHumansHypoglycemic AgentsMaleMetforminMiddle AgedMultivariate AnalysisProbabilityPrognosisProportional Hazards ModelsHypoglycemic AgentsMetformin

Identifiers

PMID20206893
PMCPMC2855621
OpenAlexW2073910667

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.